Biotechnology company Regeneron has announced its acquisition of 23andMe for $256 million following the latter's bankruptcy. Regeneron plans to continue operating 23andMe while committing to the privacy and security of its customers' genetic data. With a proven track record in genetics, Regeneron aims to utilize 23andMe's vast dataset to propel its own medical advancements. This acquisition comes amid growing consumer and regulatory concerns regarding 23andMe's data safety, highlighted by statements from California's Attorney General and the Federal Trade Commission's chairman regarding the necessity of upholding privacy policies.
As a world leader in human genetics, Regeneron Genetics Center is committed to and has a proven track record of safeguarding the genetic data of people across the globe, and, with their consent, using this data to pursue discoveries that benefit science and society.
We assure 23andMe customers that we are committed to protecting the 23andMe dataset with our high standards of data privacy, security, and ethical oversight and will advance its full potential to improve human health.
The safety of 23andMe's dataset has drawn considerable concern among consumers, lawmakers, and regulators amid the company's downfall.
In March, California Attorney General Rob Bonta made the unusual move to urge Californians to delete their genetic data amid 23andMe's financial distress.
Collection
[
|
...
]